Rezolute reports Q4 FY2024 net loss of $23M; FDA lifts partial clinical hold on ersodetug

Rezolute, Inc.

Q4 net loss $23.0M vs $12.7M prior year; full year net loss $68.5M vs $51.8M.
Cash and investments $127.1M at June 30, 2024, up from $118.4M year-over-year.
FDA lifts partial clinical holds on ersodetug for congenital HI; U.S. enrollment in Phase 3 sunRIZE expected early 2025.
Phase 3 study for tumor HI to begin H1 2025; topline results expected mid-2026.
Phase 2 RZ402 for DME met primary endpoints; partnering discussions ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.